A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A
详细信息 查看全文
- 作者：Kazuhiro Usuia ; usui@east.ntt.co.jp" class="auth_mail" title="E-mail the corresponding author ; Shunichi Sugawarab ; Masaru Nishitsujic ; Yuka Fujitad ; Akira Inouee ; Atsuto Mourif ; Hiroshi Watanabeg ; Hiroshi Sakaih ; Ichiro Kinoshitai ; Yoshihito Ohharaj ; Makoto Maemondok ; Hiroshi Kagamul ; Koichi Hagiwaram ; Kunihiko Kobayashin ; North East Japan Study Group
- 关键词：Malignant pleural effusions ; Bevacizumab ; Non-small cell lung cancer ; Lung cancer ; Pleurodesis ; Pemetrexed
- 刊名：Lung Cancer
- 出版年：2016
- 出版时间：September 2016
- 年：2016
- 卷：99
- 期：Complete
- 页码：131-136
- 全文大小：551 K
文摘
- •
We conducted the phase II trial of chemotherapy with bevacizumab in patients with MPE.
- •
MPE was well controlled without pleurodesis in patients treated with bevacizumab.
- •
Chemotherapy with bevacizumab demonstrated significant efficacy in patients with MPE.
- •
The level of VEGF in plasma and MPE might be predictive for bevacizumab-based treatment benefit.
- •
MPE: malignant pleural effusion; VEGF: vascular endothelial growth factor.